Patents by Inventor Caroline Robic
Caroline Robic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230272142Abstract: The invention relates to non-biodegradable embolisation microspheres comprising a cross-linked matrix, the matrix being based on at least: a) from 20% to 95% of hydrophilic monomer; b) from 1% to 15% of a non-biodegradable hydrophilic cross-linking monomer; and c) from 1.5% to less than 6% of transfer agent selected from alkyl halides and cycloaliphatic or aliphatic thiols having in particular from 2 to 24 carbon atoms, and optionally having another functional group selected from amino, hydroxy and carboxy groups. The invention further relates to a pharmaceutical composition comprising non-biodegradable embolisation microspheres according to the invention in conjunction with a pharmaceutically acceptable vehicle, advantageously for parenteral administration.Type: ApplicationFiled: October 7, 2020Publication date: August 31, 2023Inventors: Caroline ROBIC, Mohsen DAHESH
-
Publication number: 20230149568Abstract: The present invention relates to a complex of formula (II) constituted of at least 90% of a diastereoisomeric excess comprising a mixture of isomers II-RRR and II-SSS of formulae: The present invention also relates to a process for preparing and purifying said complex of formula (II), and also to a composition comprising said complex.Type: ApplicationFiled: January 16, 2023Publication date: May 18, 2023Inventors: Soizic LE GRENEUR, Alain CHÉNEDÉ, Martine CERF, Myriam PETTA, Emmanuelle MARAIS, Bruno FRANÇOIS, Caroline ROBIC, Stéphanie LOUGUET
-
Patent number: 11590246Abstract: The present invention relates to a complex of formula (II) constituted of at least 90% of a diastereoisomeric excess comprising a mixture of isomers II-RRR and II-SSS of formulae: The present invention also relates to a process for preparing and purifying said complex of formula (II), and also to a composition comprising said complex.Type: GrantFiled: January 17, 2020Date of Patent: February 28, 2023Assignee: GUERBETInventors: Soizic Le Greneur, Alain Chénedé, Martine Cerf, Myriam Petta, Emmanuelle Marais, Bruno François, Caroline Robic, Stéphanie Louguet
-
Patent number: 11370804Abstract: The present invention relates to a complex of formula (II) constituted of at least 90% of a diastereoisomeric excess comprising a mixture of isomers II-RRR and II-SSS of formulae: The present invention also relates to a process for preparing and purifying said complex of formula (II), and also to a composition comprising said complex.Type: GrantFiled: August 16, 2021Date of Patent: June 28, 2022Assignee: GUERBETInventors: Soizic Le Greneur, Alain Chénedé, Martine Cerf, Myriam Petta, Emmanuelle Marais, Bruno François, Caroline Robic, Stéphanie Louguet
-
Publication number: 20220062443Abstract: The present invention relates to a complex of formula (II) constituted of at least 90% of a diastereoisomeric excess comprising a mixture of isomers II-RRR and II-SSS of formulae: The present invention also relates to a process for preparing and purifying said complex of formula (II), and also to a composition comprising said complex.Type: ApplicationFiled: January 17, 2020Publication date: March 3, 2022Inventors: Soizic LE GRENEUR, Alain CHÉNEDÉ, Martine CERF, Myriam PETTA, Emmanuelle MARAIS, Bruno FRANÇOIS, Caroline ROBIC, Stéphanie LOUGUET
-
Publication number: 20210371437Abstract: The present invention relates to a complex of formula (II) constituted of at least 90% of a diastereoisomeric excess comprising a mixture of isomers II-RRR and II-SSS of formulae: The present invention also relates to a process for preparing and purifying said complex of formula (II), and also to a composition comprising said complex.Type: ApplicationFiled: August 16, 2021Publication date: December 2, 2021Inventors: Soizic LE GRENEUR, Alain CHÉNEDÉ, Martine CERF, Myriam PETTA, Emmanuelle MARAIS, Bruno FRANÇOIS, Caroline ROBIC, Stéphanie LOUGUET
-
Patent number: 10716869Abstract: The present invention relates to 18-Fluor radiolabeled macrocyclic quinazoline compounds, which are suitable as positron emission tomography (PET) tracers for imaging epidermal growth factor receptors (EGFR), and their use in in vivo diagnosis, preclinical and clinical tumour imaging, patient stratification on the basis of mutational status of EGFR, and assessing tumour response to therapeutic treatments. The present invention also describes precursor compounds and methods of preparing the radiotracers. The invention is relevant to any cancer that is influenced or driven by deregulated EGFR, such as, but not limited to, non-small cell lung cancer (NSCLC), pancreatic, hepatocellular, oesophageal, gastric, colorectal, prostate, cervical, renal, ovarian, breast cancers, head and neck squamous cell carcinoma, and malignant glioma.Type: GrantFiled: February 28, 2017Date of Patent: July 21, 2020Assignee: Oncodesign SAInventors: Jan Marie Cyriel Jozef Hoflack, Cyril Berthet, Petra Marcella Françoise Blom, Johnny Vercouillie, Caroline Robic, Sarah Catoen, Gilles Voit, Jean-Bernard Deloye
-
Patent number: 10716861Abstract: A composition in the form of a water-in-oil emulsion comprising: from 20% to 40% (v/v) of aqueous phase, in the form of droplets, comprising an anti-cancer agent and a densifying agent chosen from the complexes of nonionic macrocyclic chelate with a paramagnetic metal, from 60% to 80% (v/v) of lipid phase comprising an iodized oil and at least one surfactant of formula (I) in a proportion, by weight of surfactant relative to the total volume of the composition, of 0.3% to 5%, formula (I) of said surfactant being the following: in which: s is 0 or 1, m is an integer from 2 to 30, R1 represents a group of formula (II) in which n is an integer from 4 to 10, o is an integer from 1 to 4, p is an integer from 3 to 7, q is an integer from 2 to 10, and r is 0 or 1, R2 represents a hydrogen atom or is identical to R1, and each R3 independently represents a hydrogen atom or is identical to R1.Type: GrantFiled: August 4, 2016Date of Patent: July 21, 2020Assignee: GUERBETInventors: Caroline Robic, Jean-François Mayer
-
Publication number: 20190099496Abstract: A composition in the form of a water-in-oil emulsion comprising: from 20% to 40% (v/v) of aqueous phase, in the form of droplets, comprising an anti-cancer agent and a densifying agent chosen from the complexes of nonionic macrocyclic chelate with a paramagnetic metal, from 60% to 80% (v/v) of lipid phase comprising an iodized oil and at least one surfactant of formula (I) in a proportion, by weight of surfactant relative to the total volume of the composition, of 0.3% to 5%, formula (I) of said surfactant being the following: in which: s is 0 or 1, m is an integer from 2 to 30, R1 represents a group of formula (II) in which n is an integer from 4 to 10, o is an integer from 1 to 4, p is an integer from 3 to 7, q is an integer from 2 to 10, and r is 0 or 1, R2 represents a hydrogen atom or is identical to R1, and each R3 independently represents a hydrogen atom or is identical to R1.Type: ApplicationFiled: August 4, 2016Publication date: April 4, 2019Inventors: Caroline ROBIC, Jean-François MAYER
-
Publication number: 20190054197Abstract: The present invention relates to 18-Fluor radiolabeled macrocyclic quinazoline compounds, which are suitable as positron emission tomography (PET) tracers for imaging epidermal growth factor receptors (EGFR), and their use in in vivo diagnosis, preclinical and clinical tumour imaging, patient stratification on the basis of mutational status of EGFR, and assessing tumour response to therapeutic treatments. The present invention also describes precursor compounds and methods of preparing the radiotracers. The invention is relevant to any cancer that is influenced or driven by deregulated EGFR, such as, but not limited to, non-small cell lung cancer (NSCLC), pancreatic, hepatocellular, oesophageal, gastric, colorectal, prostate, cervical, renal, ovarian, breast cancers, head and neck squamous cell carcinoma, and malignant glioma.Type: ApplicationFiled: February 28, 2017Publication date: February 21, 2019Applicant: Oncodesign SAInventors: Jan Marie Cyriel Jozef Hoflack, Cyril Berthet, Petra Marcella Françoise Blom, Johnny Vercouillie, Caroline Robic, Sarah Catoen
-
Patent number: 9770520Abstract: The present invention relates to an oil-in-water nanoemulsion composition for MRI, comprising: an aqueous phase, representing 70% to 90% by weight of the composition, advantageously 75% to 85% and more advantageously from 78% to 82% a lipid phase comprising an oil, representing 9.5% to 29.5% by weight of the composition, advantageously 14% to 25% and more advantageously 17% to 21%, a surfactant at the interface between the aqueous and lipid phases, the surfactant comprising at least one amphiphilic paramagnetic metal chelate and optionally an amphiphilic lipid; the total content of surfactant by weight relative to the oil being between 4% and 10% and advantageously between 5% and 8%; the total content of surfactant by weight relative to the composition being between 0.35% and 2.95% and advantageously between 0.Type: GrantFiled: December 20, 2011Date of Patent: September 26, 2017Assignees: GUERBET, UNIVERSITE DE BORDEAUXInventors: Marc Port, Caroline Robic, Fernando Leal Calderon, Samy Chadel
-
Publication number: 20150320889Abstract: An oil-in-water nanoemulsion composition for MRI, comprising an aqueous phase, a lipid phase as nanodroplets comprising an oil and magnetic particles based on an iron compound and covered with one or several C8-C22 fatty acids, and a mixture of surfactants at the interface between the aqueous and lipid phases, the mixture of surfactants comprising at least one amphiphilic lipid and at least one amphiphilic targeting ligand.Type: ApplicationFiled: January 23, 2014Publication date: November 12, 2015Applicant: GUERBETInventors: Caroline Robic, Marc Port
-
Publication number: 20140234223Abstract: The invention relates to an oil-in-water nanoemulsion for MRI, including: an aqueous phase, a fluorinated phase including at least one fluorinated oil, a surfactant at the interface between the aqueous and fluorinated phases, the surfactant comprising: at least one amphiphilic targeting ligand, at least one amphiphilic lipid, and at least one diblock or triblock fluorophilic compound, as well as to the use thereof as a contrast agent.Type: ApplicationFiled: September 20, 2012Publication date: August 21, 2014Applicant: GUERBETInventors: Marc Port, Caroline Robic, Jean-Michel Fabicki
-
Publication number: 20130309176Abstract: The present invention relates to an oil-in-water nanoemulsion composition for MRI, comprising: an aqueous phase, representing 70% to 90% by weight of the composition, advantageously 75% to 85% and more advantageously from 78% to 82% a lipid phase comprising an oil, representing 9.5% to 29.5% by weight of the composition, advantageously 14% to 25% and more advantageously 17% to 21%, a surfactant at the interface between the aqueous and lipid phases, the surfactant comprising at least one amphiphilic paramagnetic metal chelate and optionally an amphiphilic lipid; the total content of surfactant by weight relative to the oil being between 4% and 10% and advantageously between 5% and 8%; the total content of surfactant by weight relative to the composition being between 0.35% and 2.95% and advantageously between 0.Type: ApplicationFiled: December 20, 2011Publication date: November 21, 2013Applicants: UNIVERSITE DE BORDEAUX 1, GUERBETInventors: Marc Port, Caroline Robic, Fernando Leal Calderon, Samy Chadel